The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Har
Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease.
Developing life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and patients to pharma and industry.
The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.